Phase 3Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (Krascendo 2)
A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Sponsor
- Hoffmann-La Roche (Industry)
- Enrolment
- 600 planned
- Conditions
- Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer
- Interventions
- Divarasib; Pembrolizumab; Pemetrexed; Carboplatin; Cisplatin
- Ages
- adults, older adults
- Registry
- NCT06793215
From the registry
The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung cancer (NSCLC).
Primary outcomes
- Progression-Free Survival (PFS)
- Overall Survival (OS)